Latest news with #SystemicLupusErythematosus
Malaysian Reserve
08-07-2025
- Business
- Malaysian Reserve
Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology
The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors include increasing clinical success, regulatory approvals, and the ability of these therapies to engage immune cells directly against tumors. Partnerships and investments from major pharmaceutical players are accelerating pipeline development. The bispecific antibody and BiTE market is also expanding beyond oncology into autoimmune and infectious diseases. LAS VEGAS, July 8, 2025 /PRNewswire/ — DelveInsight's Bispecifics/BiTE Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Acute Lymphocytic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer (NSCLC), Small-cell Lung Cancer (SCLC), Biliary Tract Cancer (BTC), Psoriasis, Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus (SLE), Wet Age-related Macular Degeneration (AMD), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging bispecifics/BiTE, market share of individual therapies, and current and forecasted bispecifics/BiTE market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the Bispecifics/BiTE Market Report As per DelveInsight's analysis, the total market size of bispecifics/BiTE in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as Acute Lymphocytic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer (NSCLC), Small-cell Lung Cancer (SCLC), Biliary Tract Cancer (BTC), Psoriasis, Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus (SLE), Wet Age-related Macular Degeneration (AMD), and others. Leading bispecifics/BiTE companies, such as Aurigene Oncology, Curis, Zenas BioPharma, I-MAB Biopharma, ABL Bio, Bristol Myers Squibb, IMBiologics, Y-Biologics, HK Innoen, Sanofi, Regeneron Pharmaceuticals, and others, are developing novel bispecifics/BiTE that can be available in the bispecifics/BiTE market in the coming years. Some of the key bispecifics/BiTE therapies in the pipeline include CA-170, Obexelimab, Givastomig, IMB-101, SAR446422, Linvoseltamab, and others. Based on pipeline activities, most of the bispecific antibodies are developed in multiple myeloma, followed by NSCLC. In June 2025, BioNTech and Bristol Myers Squibb agreed on the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate. According to Zenas BioPharma's Q1 2025 report published in May 2025, the company anticipates reporting topline Phase III results for Obexelimab in IgG4-related disease by the end of 2025, 12-week primary endpoint data in RMS in the third quarter of 2025, and 24-week primary endpoint data in SLE in the first half of 2026. In February 2025, Regeneron Pharmaceuticals announced that the US FDA the resubmission of the Biologics License Application (BLA) for linvoseltamab accepted for review for the treatment of adult patients with Relapsed/Refractory multiple myeloma who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last line of therapy. The target action date for the FDA decision is July 10, 2025. According to I-MAB Biopharma's Q1 2025 report published in May 2025, the company anticipates presenting data from the givastomig dose expansion cohorts (n = 40) in the first half of 2026, with further development initiatives and data readouts from the Phase Ib study expected through 2027. Additionally, new data from the givastomig dose escalation combination study in US patients will be presented at the European Society of Medical Oncology Gastrointestinal (ESMO GI) Cancers Congress 2025, scheduled for July 2–5 in Barcelona, Spain. In May 2025, Genentech announced two-year follow-up data from the Phase III STARGLO study. The updated data continue to demonstrate the statistically significant and clinically meaningful survival benefit of this off-the-shelf, fixed-duration Columvi combination for people with R/ DLBCL who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant (ASCT). Discover which indication is expected to grab the major bispecifics/BiTE market share @ Bispecifics/BiTE Market Report Bispecifics/BiTE Market Dynamics The bispecific antibody and BiTE market is experiencing strong momentum, driven by rapid advancements in immuno-oncology and increasing demand for precision biologics. These modalities are designed to simultaneously bind two different antigens or epitopes, commonly one on a tumor cell and the other on an immune effector cell, such as a T-cell, thereby redirecting immune activity toward malignant cells. Their ability to provide targeted immune activation while minimizing systemic toxicity positions them as highly attractive therapeutic options, particularly for difficult-to-treat cancers and hematological malignancies. Market growth is being fueled by a combination of technological innovation and clinical validation. Companies are investing heavily in next-generation bispecific platforms that offer improved stability, manufacturability, and half-life extension. Major pharmaceutical players, as well as emerging biotech firms, are advancing robust pipelines of bispecifics and BiTEs, with several candidates achieving regulatory approvals in recent years. The entry of these agents has set a precedent, increasing investor confidence and accelerating deal-making activity, including strategic collaborations and licensing agreements. Despite the enthusiasm, the bispecifics/BiTE market faces key challenges. Manufacturing complexities, immunogenicity risks, and potential for cytokine release syndrome remain technical and clinical hurdles. Additionally, the crowded competitive landscape necessitates differentiation, either through novel targets (e.g., B7-H3, DLL3, CLDN6) or superior clinical outcomes. Pricing pressures and reimbursement considerations also loom large, particularly as more therapies enter the market and stakeholders demand cost-effective value delivery. In summary, the bispecific and BiTE market represents one of the most dynamic frontiers in biologics. With many candidates in preclinical and clinical development globally, the next decade is likely to see continued maturation of the field, consolidation among players, and deeper integration of bispecifics into standard-of-care treatment paradigms. Strategic investments, patient-centric development, and continuous innovation will be critical to sustaining long-term growth. Bispecifics/BiTE Treatment Market Bispecific antibodies are designed to address complex, multifactorial diseases by simultaneously targeting two distinct disease-related molecules with a single therapeutic agent. Most approved bispecifics are used in oncology, particularly for conditions like multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Outside of oncology, only two, HEMLIBRA and VABYSMO, have been approved for treating hemophilia A, neovascular (wet) age-related macular degeneration, and diabetic macular edema. Additionally, KIMMTRAK, a bispecific molecule, has received approval specifically for uveal melanoma. REMOVAB, the world's first approved bispecific antibody, was developed to treat malignant ascites associated with solid tumors and received approval from the EMA. However, it was withdrawn from the market in 2017 due to commercial considerations. ZIIHERA is a bispecific antibody that targets HER2 by binding to two distinct extracellular domains on the receptor. In November 2024, the U.S. FDA granted accelerated approval for ZIIHERA (50 mg/mL for IV injection) for use in adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC). Zanidatamab, the molecule behind ZIIHERA, is also under evaluation in various clinical trials as a targeted therapy for solid tumors. These include Phase III studies for gastroesophageal adenocarcinoma (GEA) and metastatic breast cancer (mBC), as well as Phase II trials for colorectal and breast cancers. The drug was originally developed by Zymeworks and is now being advanced by Jazz Pharmaceuticals and BeiGene through licensing agreements. Jazz holds commercialization rights for the U.S., Europe, Japan, and all regions except Asia-Pacific territories already licensed by Zymeworks to BeiGene (excluding Japan, but including the rest of Asia, Australia, and New Zealand). In April 2025, Jazz announced its participation at the ASCO annual meeting, where three abstracts related to zanidatamab were accepted for presentation. Furthermore, the European Medicines Agency's CHMP issued a positive opinion recommending conditional marketing authorization of zanidatamab monotherapy for adults with previously treated, unresectable, locally advanced or metastatic HER2-positive (IHC 3+) BTC. COLUMVI is a bispecific antibody designed to engage CD20 and CD3, featuring a unique 2:1 structural configuration. It brings T cells into proximity with malignant B cells, making it effective in targeting cancers such as diffuse large B-cell lymphoma (DLBCL). In June 2023, the FDA granted accelerated approval to COLUMVI for use in patients with relapsed or refractory DLBCL (not otherwise specified) or large B-cell lymphoma (LBCL) that has transformed from follicular lymphoma, following at least two prior systemic treatments. Learn more about the FDA-approved bispecifics/BiTE therapies @ Bispecifics/BiTE Drugs Key Emerging Bispecifics/BiTE and Companies Several key players, including Aurigene Oncology/Curis (CA-170), I-MAB Biopharma/ABL Bio/Bristol Myers Squibb (Givastomig), IMBiologics/Y-Biologics/HK Innoen (IMB-101), Regeneron Pharmaceuticals (Linvoseltamab), Sanofi (SAR446422), Zenas BioPharma (Obexelimab), and others, are involved in developing drugs for Bispecifics/BiTE for various indications such as NSCLC, Bladder and Kidney Cancers, IgG4-RD, RMS, SLE, multiple sclerosis, and others. CA-170 is an orally administered, first-in-class small molecule with strong activity. It selectively inhibits PD-L1 and VISTA, both of which are immune checkpoint proteins that suppress immune responses. The compound is currently undergoing Phase III clinical trials for non-small cell lung cancer (NSCLC) as well as bladder and kidney cancers. In February 2020, Curis revised its collaboration and licensing agreement with Aurigene Discovery Technologies. The updated terms granted Aurigene development and commercialization rights for CA-170 across Asia, expanding on its original rights in India and Russia. Curis retained exclusive rights to the drug in the United States, Europe, and other global markets and is eligible to receive royalties from sales in Asia. The original partnership between Curis and Aurigene began in 2015. Givastomig (also referred to as TJ-CD4B/ABL111 or TJ033721) is a bispecific antibody engineered to target Claudin 18.2 (CLDN18.2) on tumor cells and activate T-cells through 4-1BB in a tumor-restricted manner. It is designed to engage tumor cells expressing varying levels of CLDN18.2, commonly found in gastric and pancreatic cancers, and locally stimulate T-cell activity within the tumor microenvironment. In September 2024, I-Mab Biopharma shared results from a Phase I trial of givastomig in patients with CLDN18.2-positive advanced gastroesophageal cancer. The therapy was well tolerated at doses up to 15 mg/kg administered biweekly and showed promising clinical activity in patients who had previously undergone multiple treatments. These patients exhibited a broad range of CLDN18.2 expression. Earlier, in March 2022, the FDA granted givastomig Orphan Drug Designation for the treatment of gastric and gastroesophageal junction cancers. The anticipated launch of these emerging therapies are poised to transform the bispecifics/BiTE market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the bispecifics/BiTE market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about bispecifics/BiTE clinical trials, visit @ Bispecifics/BiTE Treatment Drugs Bispecifics/BiTE Overview Bispecific antibodies, including Bispecific T-cell Engagers (BiTEs), represent an innovative class of immunotherapies designed to harness the immune system to target and destroy cancer cells more precisely. Unlike conventional monoclonal antibodies, bispecifics are engineered to recognize and bind to two different antigens simultaneously. One arm typically targets a tumor-associated antigen on cancer cells, while the other engages a molecule on immune cells, most commonly CD3 on T cells. This dual targeting brings T cells into close proximity with tumor cells, triggering T-cell activation and cytotoxicity, even without the need for antigen presentation or co-stimulation. BiTEs are a specific subset of bispecifics characterized by their compact size and lack of an Fc region, enabling better tissue penetration and faster pharmacokinetics. The most well-known example is blinatumomab, approved for treating certain types of B-cell acute lymphoblastic leukemia. As research expands, next-generation BiTEs and bispecifics are being developed to improve half-life, reduce off-target effects, and address solid tumors, traditionally more challenging for immunotherapy. Their modular design also enables customization to different tumor types and immune targets, making them a versatile and rapidly advancing segment of oncology therapeutics. Bispecifics/BiTE Epidemiology Segmentation The bispecifics/BiTE market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for Bispecifics/BiTE Total Eligible Patient Pool in Selected Indications for Bispecifics/BiTE Total Treated Cases in Selected Indications for Bispecifics/BiTE Bispecifics/BiTE Report Metrics Details Study Period 2020–2034 Bispecifics/BiTE Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Acute Lymphocytic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer (NSCLC), Small-cell Lung Cancer (SCLC), Biliary Tract Cancer (BTC), Psoriasis, Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus (SLE), Wet Age-related Macular Degeneration (AMD), and others Key Bispecifics/BiTE Companies Aurigene Oncology, Curis, Zenas BioPharma, I-MAB Biopharma, ABL Bio, Bristol Myers Squibb, IMBiologics, Y-Biologics, HK Innoen, Sanofi, Regeneron Pharmaceuticals, Zymeworks, Genentech, Genmab, Pfizer, Johnson & Johnson Innovative Medicine, AstraZeneca, and others Key Bispecifics/BiTE Therapies CA-170, Obexelimab, Givastomig, IMB-101, SAR446422, Linvoseltamab, ZIIHERA, COLUMVI, EPKINLY, LUNSUMIO, ELREXFIO, VABYSMO, TECVAYLI, SAPHNELO, OCREVUS, and others Scope of the Bispecifics/BiTE Market Report Bispecifics/BiTE Therapeutic Assessment: Bispecifics/BiTE current marketed and emerging therapies Bispecifics/BiTE Market Dynamics: Conjoint Analysis of Emerging Bispecifics/BiTE Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Bispecifics/BiTE Market Access and Reimbursement Discover more about bispecifics/BiTE therapies in development @ Bispecifics/BiTE Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Key Highlights Of The Report 4 Executive Summary Of Bispecifics/BiTE 5 Key Events 6 Epidemiology And Market Forecast Methodology 7 Bispecific/BiTE Market Overview At A Glance 7.1 Market Share (%) Distribution of Bispecifics/BiTE by Therapies in 2024 7.2 Market Share (%) Distribution of Bispecifics/BiTE by Therapies in 2034 7.3 Market Share (%) Distribution of Bispecifics/BiTE by Indications in 2024 7.4 Market Share (%) Distribution of Bispecifics/BiTE by Indications in 2034 8 Background And Overview 8.1 Introduction 8.2 Treatment 8.3 FDA-Approved Bispecifics/BiTE Antibodies 9 Epidemiology And Patient Population 9.1 Key Findings 9.2 Assumptions And Rationale 9.3 Total Cases of Selected Indication for Bispecifics/BiTE in the 7MM 9.4 The eligible pool of Indications for Bispecific/BiTE Antibodies in the 7MM 9.5 Treatable Cases by Indication for Bispecific/BiTE Antibodies in the 7MM 10 Marketed Drugs 10.1 Key Competitors 10.2 ZIIHERA (zanidatamab): Zymeworks 10.2.1 Product Description 10.2.2 Regulatory Milestones 10.2.3 Other Developmental Activities 10.2.4 Clinical Development 10.2.4.1 Clinical Trial Information 10.2.5 Safety and Efficacy 10.2.6 Analyst Views 10.3 COLUMVI (glofitamab): Roche 10.3.1 Product Description 10.3.2 Regulatory Milestones 10.3.3 Other Developmental Activities 10.3.4 Clinical Development 10.3.4.1 Clinical Trial Information 10.3.5 Safety and Efficacy 10.3.6 Analyst Views List to be continued… 11 Emerging Drugs 11.1 Key Competitors 11.2 CA-170: Aurigene Oncology and Curis 11.2.1 Product Description 11.2.2 Other Development Activities 11.2.3 Clinical Development 11.2.3.1 Clinical Trials Information 11.2.4 Safety and Efficacy 11.2.5 Analyst Views 11.3 Givastomig: I-MAB Biopharma, ABL Bio, and Bristol Myers Squibb 11.3.1 Product Description 11.3.2 Other Development Activities 11.3.3 Clinical Development 11.3.3.1 Clinical Trials Information 11.3.4 Safety and Efficacy 11.3.5 Analyst Views List to be continued… 12 Bispecifics/BiTE: The 7MM Analysis 12.1 Key Findings 12.2 Market Outlook 12.3 Conjoint Analysis 12.4 Key Market Forecast Assumptions 12.4.1 Cost Assumptions and Rebates 12.4.2 Pricing Trends 12.4.3 Analogue Assessment 12.4.4 Launch Years and Therapy Uptake 12.5 Total Market Size of Bispecifics/BiTE in the 7MM 12.6 United States Market 12.6.1 Market Size of Bispecifics/BiTE By Indications in the United States 12.6.2 Market Size By Therapies in the United States 12.7 EU4 and the UK Market 12.7.1 Market Size of Bispecifics/BiTE By Indications in EU4 and the UK 12.7.2 Market Size By Therapies in EU4 and the UK 12.8 Japan Market 12.8.1 Market Size of Bispecifics/BiTE By Indications in Japan 12.8.2 Market Size By Therapies in Japan 13 Unmet Needs Of Bispecifics/BiTE 14 SWOT Analysis Of Bispecifics/BiTE 15 KOL Views Of Bispecifics/BiTE 16 Market Access and Reimbursement 16.1 United States 16.1.1 Centre for Medicare & Medicaid Services (CMS) 16.2 EU4 and the UK 16.2.1 Germany 16.2.2 France 16.2.3 Italy 16.2.4 Spain 16.2.5 United Kingdom 16.3 Japan 16.3.1 MHLW 17 Appendix 17.1 Bibliography 17.2 Report Methodology 18 DelveInsight Capabilities 19 Disclaimer 20 About DelveInsight Related Reports Non-Small Cell Lung Cancer Market Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including AstraZeneca, Boehringer Ingelheim, Pfizer, Takeda, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Merck, Bristol-Myers Squibb, Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma, Moderna Therapeutics, Pfizer, GSK, Gilead Sciences, BieGene, Nuvalent, among others. Small Cell Lung Cancer Market Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SCLC companies, including Ascentage Pharma, Merck & Co., AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, among others. Diffuse Large B-cell Lymphoma Market Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DLBCL companies, including AbbVie, Genmab, Merck, Roche, Xencor, Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, AstraZeneca, Gilead Sciences, among others. Multiple Myeloma Market Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Sanofi, Karyopharm Therapeutics, AbbVie, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie, Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content:
Bangkok Post
05-07-2025
- Health
- Bangkok Post
Calls to improve treatment and access for people living with HIV
The Thai Network of People Living with HIV/AIDS (TNP+) has called on Public Health Minister Somsak Thepsuthin to improve the universal coverage scheme, otherwise known as the gold card scheme, to ensure broader access to healthcare for people with HIV/Aids. Apiwat Kwangkaew, vice president of the TNP+, on Saturday said the proposal was made at the annual national health security meeting held by the National Health Security Office (NHSO) on June 30. Mr Somsak is also chair of the NHSO board. The aim is to improve the gold card scheme in three key areas including allowing those younger than 18 to receive treatment for Hepatitis C. For Hepatitis B, although treatment is covered, access to testing and medication remains limited, as the costs are included in the capitation budget -- a fixed amount of money paid regardless of the number of services provided. They also urged inclusion of the Hepatitis B vaccine for those with lower immune defences for early prevention, and proposed the expansion of cervical cancer screening for high-risk groups. That would include those with HIV, Systemic Lupus Erythematosus and immunocompromised people and begin at the age of 25, with screening every three years. Expansion of the "One ID Card, Treatment Anywhere" policy to include antiretroviral (ARV) services, and cooperation with state enterprise employers to solve reimbursement delays are also planned. Also, the network called for nationwide anti-discrimination policies for people with HIV/Aids and urged the NHSO to coordinate with Disease Control Department, Thai AIDS Society and other networks to ensure efficient communications. The network also proposed a more proactive approach to healthcare in Bangkok such as allowing pharmacies to provide medications for those with non-communicable diseases and ensuring wider access for the "One ID Card, Treatment Anywhere" policy.
Barnama
23-06-2025
- Health
- Barnama
PM Anwar Extends Aid To Struggling Hawker Family Battling Illness And Poverty
KUALA LUMPUR, June 23 (Bernama) -- Prime Minister Datuk Seri Anwar Ibrahim has extended financial assistance to a small-time hawker in Kuantan, Pahang, Mohd Zaki Che Ibrahim, 45, who has been struggling to repair his dilapidated home and care for his family, including a wife battling a chronic illness. The donation was presented by the Prime Minister's Political Secretary, Datuk Ahmad Farhan Fauzi, during a visit to the couple and their 18-year-old son under the Ziarah MADANI outreach programme. 'Every morning, Mohd Zaki sells breakfast at his small stall to support his family. 'Despite his wife's unstable health condition due to Systemic Lupus Erythematosus (SLE), they persevere to keep the kitchen running and provide for their son,' Ahmad Farhan wrote in a Facebook post, which was also shared by the Prime Minister. According to Ahmad Farhan, the family's home is in poor condition, with a leaking roof, broken floor and cracked walls, adding to the daily challenges they face. 'As part of the Ziarah MADANI initiative, I came on behalf of the Prime Minister to deliver aid and assess what forms of assistance should be expedited to help this family live in safer and more comfortable conditions,' he said. Ahmad Farhan also expressed hope that the support offered would provide some relief to the family. 'Behind that breakfast stall lies a story of resilience unknown to many… and behind this gesture is a silent prayer that they will no longer have to endure hardship alone,' he added. -- BERNAMA
NDTV
11-06-2025
- Health
- NDTV
Can The Ice Dunk Trend Save Your Skin? We Asked Experts
Summer doesn't exactly scream "beauty trend season," but one skincare practise is climbing the charts and rightly so - the ice dunking trend. From Alia Bhatt using ice to reduce puffiness to Ananya Panday showcasing it as a cool beauty hack that works, ice dunking has become a favourite among many celebrities. While ice has always been a popular element in skincare rituals, the recent trend has us curious about its real benefits. NDTV reached out to experts to better understand both the advantages and disadvantages of this growing skincare practise. What Is Ice Dunking For Skin? Dunking ice for skin- also known as ice dunking or an ice water facial - is a popular beauty trend where you submerge your face in a bowl full of ice-cold water for a short period. It is sort of a cold therapy believed to refresh and rejuvenate the skin. Benefits Of Ice Dunking For Skin From improving skin texture to reducing inflammation, ice dunking offers several benefits - but do they actually last? We asked experts. Dr Meghana Reddy Endela, Consultant Dermatologist at Zennara Clinics, told NDTV that ice dunking improves circulation, reduces inflammation, enhances skin health, and may even regulate core body temperature. "Cold water has anti-inflammatory benefits and soothes irritated, itchy skin. It refreshes the skin, especially in hot weather. Cold water is also known to have a temporary benefit on enlarged pores and improving skin tone due to the vasoconstriction effect," explains Dr Madhuri Agarwal, Dermatologist, Founder & Medical Director at Yavana Aesthetics Clinic. Dr Rashmi Sharma, Dermatologist and Director at Kara Dermatology Solutions & Aesthetic Centre, agrees that while ice dunking can benefit the skin, it does have not have a long-term effect. "It can temporarily shrink the pores and make your skin shine, which will make the redness reduce". Are There Any Side Effects Of Ice Dunking As the trend gains popularity, many people follow it blindly without understanding the potential side effects, which may lead to skin issues. Dr Endela says, "Beginners should start by dipping their face in ice for about 15 seconds and gradually increase to 30 seconds. It's important to take breaks between plunges to avoid problems. People with sensitive skin need to be careful, as cold water can strip the skin of natural oils, causing skin irritation and dryness". Who Should Avoid Ice Dunking You may want to hop on the bandwagon when there's a new skincare trend around, but it's crucial to evaluate whether it suits your skin type. Experts recommend avoiding ice dunking in certain cases: If you have rosacea (a chronic inflammatory skin condition) as extreme temperatures can trigger a flare-up. Those who suffer from circulatory issues such as Systemic Lupus Erythematosus (an autoimmune disease where the body's immune system mistakenly attacks healthy tissues) and Raynaud (a condition that causes the blood vessels in the extremities, typically fingers and toes). People who have sensitive skin as it may cause irritation and skin damage. Ice dunking can make it worse if you are prone to broken capillaries. You should not try it if you have severe acne. While it may soothe inflammation, can irritate lesions.
The Citizen
04-06-2025
- General
- The Citizen
NGOs raise lupus awareness with fun walk
The annual 10km Lupus Awareness Fun Walk took place on May 31 in Mamelodi. World Lupus Day is recognised on May 10. We Also Sparkle and Waratwa foundations held the walk to close off the awareness month and shine a spotlight on the illness. Systemic Lupus Erythematosus (SLE), also known as lupus, is an autoimmune disease that affects each individual differently. Lupus affects both men and women, and symptoms range from fatigue to joint pain and skin rashes and can affect multiple organs. The awareness walk started in Mamelodi East on Motsumi Street, Ext 4, Moon Park to Top T in Nellmapius and back, making up a distance of the 10km. The day started with a warm-up session by Adventure for Fun to get participants ready for the walk and ended with a festival of colours. Speakers from both NGOs and partnering organisations spoke on the importance of annual events that commemorate serious illness. 'What I can say is that with your support, we will be able to spread awareness about lupus across the country. The more people are aware of lupus, the fewer people with die from it. At least if you know you have lupus, you can manage it. Others don't even get that chance because it kills the organs in the body, and by the time it's diagnosed, it's too late,' Komati said. She added that, despite having flare-ups and challenges, giving in to the disease is not an option. She also insisted that those living with lupus register on their website, as there are currently no statistics regarding lupus in South Africa. Tisetso Khuele (31), a resident living with lupus, said that without the support of close friends and family, the disease would have claimed her life long ago. 'My symptoms first started with my feet swelling, my hands turning blue, I'd pass out randomly, and it only got worse throughout the years until I was diagnosed with lupus in 2009. The symptoms started when I was 14, but I didn't know what it was. No one knew lupus, and where do you even start? So, I was shocked because it was something new, so we had to search for specialists, I had to find a doctor to help me manage the condition,' Khuele said. She added that since being on medication, she can live more easily, maintain a job and a healthy lifestyle. She dedicated her walk to friends who have died from lupus and urged those who receive their diagnosis to keep pushing, as they can still make it. Her mother, Esther Khuele, said her wish was that more mothers and daughters would attend campaigns such as these, as though lupus can affect men, it's more prevalent among women. Esther is the founder of Lila Butterfly Lupus Foundation. 'As Tiseto mentioned, her symptoms began at 14. That's a tender age where you think it's just changes related to adolescence, the fatigue and things like mood changes can be chalked up to a child being a child, not realising something big is on the horizon. We've experienced days where we woke up with her hands and feet being blue, I'm talking blue like denim. She's not talking, eyes protruding out of the sockets, lung issues, being exposed to the sun, there were times we had to cut vacations short because of it,' Esther said. She said more education is needed about the disease as it is a silent killer, claiming young and old lives alike. Her organisation intends to spread the message till the country is sensitised to Lupus. Do you have more information about the story? Please send us an email to bennittb@ or phone us on 083 625 4114. For free breaking and community news, visit Rekord's websites: Rekord East For more news and interesting articles, like Rekord on Facebook, follow us on Twitter or Instagram At Caxton, we employ humans to generate daily fresh news, not AI intervention. Happy reading!
